Results Of General Meeting, page-12

1. Still no explanation of the 22 December 2017 announcement regarding CE Mark and FDA approval, where the market was advised the approvals would be well with the first quarter and well within the first half respectively. The new Chairman needs to investigate this as a priority and ensure it doesn't happen again.

2. The good news? These matters are firmly in the hands of CZM and not Optiscan so it will happen and CZM will adhere to the process.

3. CE Mark and FDA approvals should peak the interest of institutional investors, if they pile in then we may see better outcomes at the AGM.

4. All the same, there must be some head shaking at CZM. However, I suspect they are all over what is going on like the proverbial fat boy on a cupcake.

5. Remember, he who laughs last laughs longest.